Work

Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.lba5528

Authors: I. Vergote, N. Finkler, J. del Campo, A. Lohr, J. Hunter, D. Matei, D. Spriggs, J. Kavanagh, J. Vermorken, G. L. Brown, S. Kaye

Institutions: Memorial Sloan Kettering Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Telik, Inc. (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596983980

Cites:

Cited by: 20

Related to: 10